Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $107.63, marking a +0.62% move from the previous day.

AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?

by Zacks Equity Research

AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Pfizer (PFE) to Buy Seagen for $43B, Boost Cancer Portfolio

by Zacks Equity Research

Pfizer (PFE) is set to buy Seagen (SGEN) in a $43 billion deal. Seagen's key products focus on cancer treatment.

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK

by Kinjel Shah

FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.

Merck (MRK) Stock Moves -0.63%: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $107.60, marking a -0.63% move from the previous day.

Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept

by Zacks Equity Research

Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.

Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl

by Zacks Equity Research

Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.

Zacks Value Investor Highlights: Merck, Coca-Cola, Coca-Cola Consolidated, American Express and Chevron

by Zacks Equity Research

Merck, Coca-Cola, Coca-Cola Consolidated, American Express and Chevron have been highlighted in this Value Investor article.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $106.88 in the latest trading session, marking a -0.12% move from the prior day.

Tracey Ryniec headshot

Secrets of Great Long-Term Stock Investors

by Tracey Ryniec

Even Warren Buffett admits there's a lot of luck involved in investing.

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

by Zacks Equity Research

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Corcept's (CORT) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Corcept Therapeutics' (CORT) fourth-quarter earnings and revenues lag estimates.

Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil

by Zacks Equity Research

Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.

Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.

Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ

by Zacks Equity Research

Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo

by Kinjel Shah

FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.

Stock Market News for Feb 24, 2023

by Zacks Equity Research

U.S. stock markets closed higher on Thursday after a choppy session.

Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y

by Zacks Equity Research

Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA

by Zacks Equity Research

The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.

Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.

Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.